The clinical success of monoclonal antibodies to treat diseases across nearly every therapeutic area has spurred advances in bispecific antibody technology with the goal of cost-effectively combining various therapies or providing novel mechanisms for disease intervention. Many novel bispecific antibodies are now in clinical development or the late pre-clinical setting. A new horizon exists for novel molecular entities with the ability to bind three or more antigens. Here we describe the production and characterization of novel trispecific antibody-like proteins denoted 'OrthoTsAbs' that self-assemble through the application of engineered antibody domain interfaces.

中文翻译：

---

基于正交Fab的三特异性抗体形式的产生。

单克隆抗体治疗几乎每个治疗领域的疾病在临床上的成功推动了双特异性抗体技术的发展，其目标是经济有效地组合各种疗法或提供新的疾病干预机制。现在许多新的双特异性抗体正在临床开发中或在临床前后期使用。具有结合三种或更多种抗原的能力的新型分子实体存在新的视野。在这里，我们描述了新型三特异性抗体样蛋白（称为“ OrthoTsAbs”）的产生和表征，这些蛋白通过应用工程化抗体域界面进行自组装。